Glyscend’s dynamic barrier approach seeks to provide the benefits of gastric bypass surgery and duodenal exclusion devices to type 2 diabetic, overweight, and/or obese patients without the need for an invasive surgery or procedure.
Mimicking the effect of bariatric surgery with an oral pill
Our uniquely designed drugs, based on a polymer therapeutic platform, are taken orally and can non-invasively mimic the physiology of bariatric surgery.
Leveraging decades of experience in gastroenterology, metabolism, polymer chemistry, and drug development
Glyscend’s team has contributed to over 25 FDA-approved therapeutic products, many being first-in-class, including Byetta®, Bydureon®, Renagel®, and Welchol®.
Latest News
Press Release | June 3, 2024
Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease
Press Release | September 5, 2023